Screener
Corvus Pharmaceuticals CRVS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $253,195 | $71,119 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,697 | $2,491 |
| Operating lease liability | 428 | 403 |
| Accrued and other liabilities | 6,985 | 6,486 |
| Total current liabilities | 12,110 | 9,380 |
| Operating lease liability | 406 | 534 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's accounts payable?
- Corvus Pharmaceuticals (CRVS) reported accounts payable of $4.7M in Q1 2026.
- How has Corvus Pharmaceuticals's accounts payable changed year-over-year?
- Corvus Pharmaceuticals's accounts payable increased by 259.1% year-over-year, from $1.31M to $4.7M.
- What is the long-term trend for Corvus Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's accounts payable has grown at a -6.4% compound annual growth rate (CAGR), from $3.47M to $2.49M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Corvus Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude